Incremental pharmaceutical innovation benefits Indian patients and leads to a higher quality of life, just as it has across the world. In recent years, pharmaceutical innovation has accounted for as much as 65% of new drug approvals by regulatory agencies and more than 60% of the drugs on the World Health Organization list of essential medicines. This reflects the incremental innovation of older drugs. Currently, India’s patent law [Section 3(d)] discriminates against a large portion of valuable pharmaceutical innovation.

A report released by The Coalition for Healthy India,“The Value of Incremental Pharmaceutical Innovation: Benefits for Indian Patients and Indian Business"  focuses on the impact of restrictive policies in India with respect to medical and pharmaceutical innovation.